Feature | May 15, 2014

Linking Vascular Inflammation to Obesity, Atherosclerosis


May 15, 2014 — A clinical study in The Journal of Experimental Medicine shows that I?B kinase ? (IKK?) functions in smooth muscle cells to regulate vascular inflammatory responses and atherosclerosis development.

Inflammatory responses are the driving force of atherosclerosis, a process that involves the hardening and thickening of artery walls due to excess fatty deposits. IKK? is a central coordinator of inflammatory responses that has been implicated in vascular diseases, but its role in atherosclerosis has been unclear.

Now, Changcheng Zhou and colleagues from the University of Kentucky show that deficiency of IKK? in smooth muscle cells decreases vascular inflammation and atherosclerosis development in mice. Surprisingly, the lack of IKK? also blocks the differentiation of fat cells and causes an accumulation of body fat precursor cells, thus protecting the animals from diet-induced obesity. These novel findings suggest that the kinase acts as a regulator of fat cell differentiation. The use of IKK? inhibitors may therefore provide an innovative treatment for atherosclerosis, obesity, and metabolic disorders.

Sui, Y., et al. 2014. J. Exp. Med.doi:10.1084/jem.20131281

For more information: www.jem.org


Related Content

News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
Subscribe Now